Eileen N Phan1, Steven W Thorpe2, Felix S Wong3, Augustine M Saiz4, Sandra L Taylor5, Robert J Canter6, Leon Lenchik7, R Lor Randall2, Robert D Boutin8. 1. School of Medicine, University of California, Davis, Sacramento, California. 2. Sarcoma Services, Department of Orthopaedic Surgery, University of California, Davis, Sacramento, California. 3. Department of Radiology, University of California, Davis, Sacramento, California. 4. Department of Orthopaedic Surgery, University of California, Davis, Sacramento, California. 5. Department of Public Health Sciences, University of California, Davis, Sacramento, California. 6. Division of Surgical Oncology, Department of Surgery, University of California, Davis, Sacramento, California. 7. Department of Radiology, Wake Forest School of Medicine, Winston-Salem, North Carolina. 8. Department of Radiology, Stanford University, Stanford, California.
Abstract
BACKGROUND AND OBJECTIVES: Computed tomography (CT) measurements of sarcopenia have been proposed as biomarkers associated with outcomes in various cancers and have typically been evaluated at the L3 vertebral level. However, staging imaging for patients with extremity and truncal soft tissue sarcoma (STS) often only includes chest CT imaging which precludes evaluation at L3. Therefore, we sought to evaluate muscle metrics at T12 on standard staging chest CT scans and evaluate for correlation with overall and event-free survival in patients with STS. METHODS: CT chest imaging for 89 patients with intermediate and high-grade STS (53 male, 36 female; 58.5 ± 19.0 years old, follow-up 37.4 ± 27.1 months) was reviewed on PACS at T12 for skeletal muscle density (SMD) and skeletal muscle index (SMI). RESULTS: Overall survival increased with increased SMD on univariate (hazard ratio [HR] = 0.61 [0.43, 0.86]) and age-adjusted analysis (HR = 0.65 [0.42, 0.89]. Event-free survival also increased with increased SMD in univariate analyses (HR = 0.68 [0.49, 0.95]) but did not maintain significance after adjusting for age (HR = 0.68 [0.43, 1.07]). SMI was not a predictor of overall or event-free survival. CONCLUSIONS: Higher SMD measured on routinely obtained staging chest CTs in STS patients is associated with improved survival.
BACKGROUND AND OBJECTIVES: Computed tomography (CT) measurements of sarcopenia have been proposed as biomarkers associated with outcomes in various cancers and have typically been evaluated at the L3 vertebral level. However, staging imaging for patients with extremity and truncal soft tissue sarcoma (STS) often only includes chest CT imaging which precludes evaluation at L3. Therefore, we sought to evaluate muscle metrics at T12 on standard staging chest CT scans and evaluate for correlation with overall and event-free survival in patients with STS. METHODS: CT chest imaging for 89 patients with intermediate and high-grade STS (53 male, 36 female; 58.5 ± 19.0 years old, follow-up 37.4 ± 27.1 months) was reviewed on PACS at T12 for skeletal muscle density (SMD) and skeletal muscle index (SMI). RESULTS: Overall survival increased with increased SMD on univariate (hazard ratio [HR] = 0.61 [0.43, 0.86]) and age-adjusted analysis (HR = 0.65 [0.42, 0.89]. Event-free survival also increased with increased SMD in univariate analyses (HR = 0.68 [0.49, 0.95]) but did not maintain significance after adjusting for age (HR = 0.68 [0.43, 1.07]). SMI was not a predictor of overall or event-free survival. CONCLUSIONS: Higher SMD measured on routinely obtained staging chest CTs in STS patients is associated with improved survival.
Authors: Sarah P Psutka; Stephen A Boorjian; Michael R Moynagh; Grant D Schmit; Brian A Costello; R Houston Thompson; Suzanne B Stewart-Merrill; Christine M Lohse; John C Cheville; Bradley C Leibovich; Matthew K Tollefson Journal: J Urol Date: 2015-08-18 Impact factor: 7.450
Authors: Michael S Sabel; Jay Lee; Shijie Cai; Michael J Englesbe; Stephen Holcombe; Stewart Wang Journal: Ann Surg Oncol Date: 2011-08-06 Impact factor: 5.344
Authors: Robert D Boutin; Justin M Kaptuch; Cyrus P Bateni; James S Chalfant; Lawrence Yao Journal: AJR Am J Roentgenol Date: 2016-08-24 Impact factor: 3.959
Authors: Carla M M Prado; Vickie E Baracos; Linda J McCargar; Tony Reiman; Marina Mourtzakis; Katia Tonkin; John R Mackey; Sheryl Koski; Edith Pituskin; Michael B Sawyer Journal: Clin Cancer Res Date: 2009-04-07 Impact factor: 12.531
Authors: Robert J Wilson; Vignesh K Alamanda; Katherine G Hartley; Nathan W Mesko; Jennifer L Halpern; Herbert S Schwartz; Ginger E Holt Journal: Sarcoma Date: 2015-12-01
Authors: Eileen N Phan; Steven W Thorpe; Felix S Wong; Augustine M Saiz; Sandra L Taylor; Robert J Canter; Leon Lenchik; R Lor Randall; Robert D Boutin Journal: J Surg Oncol Date: 2020-07-01 Impact factor: 3.454
Authors: Dennis Strassmann; Bennet Hensen; Viktor Grünwald; Katharina Stange; Hendrik Eggers; Florian Länger; Mohamed Omar; Patrick Zardo; Hans Christiansen; Christoph W Reuter; Frank K Wacker; Arnold Ganser; Philipp Ivanyi Journal: Int J Clin Oncol Date: 2021-07-27 Impact factor: 3.402